» Articles » PMID: 11527419

R(+)-methanandamide Induces Cyclooxygenase-2 Expression in Human Neuroglioma Cells Via a Non-cannabinoid Receptor-mediated Mechanism

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2001 Aug 31
PMID 11527419
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Cannabinoids affect prostaglandin (PG) formation in the central nervous system through as yet unidentified mechanisms. Using H4 human neuroglioma cells, the present study investigates the effect of R(+)-methanandamide (metabolically stable analogue of the endocannabinoid anandamide) on the expression of the cyclooxygenase-2 (COX-2) enzyme. Incubation of cells with R(+)-methanandamide was accompanied by concentration-dependent increases in COX-2 mRNA, COX-2 protein, and COX-2-dependent PGE(2) synthesis. Moreover, treatment of cells with R(+)-methanandamide in the presence of interleukin-1beta led to an overadditive induction of COX-2 expression. The stimulatory effect of R(+)-methanandamide on COX-2 expression was mimicked by the structurally unrelated cannabinoid Delta(9)-tetrahydrocannabinol. Stimulation of both COX-2 mRNA expression and subsequent PGE(2) synthesis by R(+)-methanandamide was not affected by the selective CB(1) receptor antagonist AM-251 or the G(i/o) protein inactivator pertussis toxin. Enhancement of COX-2 expression by R(+)-methanandamide was paralleled by time-dependent phosphorylations of p38 mitogen-activated protein kinase (MAPK) and p42/44 MAPK. Consistent with the activation of both kinases, R(+)-methanandamide-induced COX-2 mRNA expression and PGE(2) formation were abrogated in the presence of specific inhibitors of p38 MAPK (SB203580) and p42/44 MAPK activation (PD98059). Together, our results demonstrate that R(+)-methanandamide induces COX-2 expression in human neuroglioma cells via a cannabinoid receptor-independent mechanism involving activation of the MAPK pathway. In conclusion, induction of COX-2 expression may represent a novel mechanism by which cannabinoids mediate PG-dependent effects within the central nervous system.

Citing Articles

Emerging Lipid Targets in Glioblastoma.

Darwish A, Pammer M, Gallyas Jr F, Vigh L, Balogi Z, Juhasz K Cancers (Basel). 2024; 16(2).

PMID: 38254886 PMC: 10814456. DOI: 10.3390/cancers16020397.


Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2.

Scholl A, Ivanov I, Hinz B Oncotarget. 2016; 7(38):61438-61457.

PMID: 27556861 PMC: 5308663. DOI: 10.18632/oncotarget.11367.


Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth.

Van Dross R, Soliman E, Jha S, Johnson T, Mukhopadhyay S Life Sci. 2012; 92(8-9):463-6.

PMID: 23069587 PMC: 4226396. DOI: 10.1016/j.lfs.2012.09.025.


The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein.

Fiori J, Sanghvi M, OConnell M, Krzysik-Walker S, Moaddel R, Bernier M Br J Pharmacol. 2011; 164(3):1026-40.

PMID: 21449913 PMC: 3195923. DOI: 10.1111/j.1476-5381.2011.01384.x.


Changes in the endocannabinoid system may give insight into new and effective treatments for cancer.

Alpini G, DeMorrow S Vitam Horm. 2009; 81:469-85.

PMID: 19647123 PMC: 2791688. DOI: 10.1016/S0083-6729(09)81018-2.